FDA clears Current Health’s hospital-to-home wearable, combining analytics and passive vital sign tracking

CONOR HALE | April 25, 2019 | 286 views

The FDA has cleared Current Health’s wearable tracker, designed to be taken home from the hospital after acute care to track a patient’s recovery in real time, with the ultimate goal of reducing readmissions. The 510(k) clearance covers the Class II device and Current’s telehealth platform, which offers a dashboard for physicians, AI-based risk prediction and alerts, as well as secure video chat. Meanwhile, the patient-facing side—delivered via a Current-issued tablet—includes medication reminders, automated symptom questionnaires and HIPAA-compliant text messaging.

Spotlight

Adamed Laboratorios S.L.U.

ADAMED is an international laboratory specializing in Central Nervous System (CNS) and in the area of ​​Gynecology with Adamed Woman. With a young and dynamic style, we offer new answers adapted to the daily needs of the specialist in these areas. Our presence in Spain is backed by a solid position in R & D, giving us completely to innovation, quality and service. Dedicating ourselves to our work in body and mind. MISSION: Develop and offer products and services of the best quality.

OTHER ARTICLES
PHARMA TECH

Tips for Managing Chronic Pain Beyond Prescription Painkillers

Article | August 9, 2022

Painkillers like Oxycontin, Percocet, and Vicodin, have been prescribed by primary physicians, surgeons, dentists, and other healthcare providers to patients suffering from varying levels of pain. Though these medications have proven to be an effective source of pain relief, they have also proven to be highly addictive. In fact, it has even been reported that there are more cases of a drug overdose and deaths from prescription painkillers than heroin or cocaine. While there are a number of factors that play into this opioid epidemic, educating doctors and patients on alternative solutions to managing chronic pain is a great place to start combatting this nationwide crisis.

Read More
PHARMA TECH

What are the advantages of PCD Pharma Company?

Article | July 7, 2022

PCD Pharma stands for propaganda distribution. A PCD company gives brand name and support to its franchises. They also provide distribution rights and monopoly rights within a particular region. If a person wants to establish their business, it is a must for them to know the pros and cons of the business to make a sound decision. Needless to mention that PCD company has a lot to contribute in the medical filed. Worldwide in a medical field, A PCD Pharma Company is playing an essential and crucial role in the rapid growth. The pharma industry is progressing t a fast pace. The company uses the latest technologies for each brand which ensures the safety of products and accepts the responsibility of human health & life by providing better outcomes. To have a drug license number and company registration, the cost to establish the company is quite cost-effective that is15000-20000rs. So this gives people a brilliant opportunity to have their unit without digging a big hole in their bank balance. Indian produces exquisite quality products, which make pharma companies a considerable success.

Read More
PHARMA TECH

WALGREEN’S IN HOT WATER OVER PHONY PHARMACIST

Article | July 12, 2022

The drugstore chain agreed to pay $7.5 million in fines after an unlicensed pharmacist at several San Francisco Bay locations illegally filled more than 700,000 prescriptions over a ten-year period. According to California prosecutors, Kim Thien Le stole license numbers from other pharmacists to fill prescriptions for Fentanyl, morphine, and other painkillers. Le pleaded guilty to multiple felony impersonation counts. Walgreen’s agreed to the settlement to avoid being charged with consumer fraud in Alameda and Santa Anna Counties. Prosecutors alleged that Walgreen’s failed to verify Le’s license and did not conduct a thorough background check. The company insisted it has taken remedial measures.

Read More

How Can Medical Cannabis Help to Manage Pain Conditions? – The Cannabis Exchange

Article | February 11, 2020

Pain management is one of the most common reasons for the use of medical cannabis products. However, despite many jurisdictions – including Canada, Germany, and the Netherlands – now allowing the prescription of medical cannabis for this purpose, there remains little ‘high-quality’ evidence to support, or oppose its efficacy. Madden et al. (2018) set out to review the evidence available in order to determine the efficacy of medical cannabis when employed in the management of various forms of musculoskeletal pain. The researchers analysed various studies that assessed the use of cannabinoids in the treatment of arthritis pain; back pain; postoperative pain; and trauma-related pain. It is estimated that up to 30% of the population may suffer from a non-cancer-related pain condition. As such a high percentage of people suffer from these conditions, the development of simple and safe therapies is an essential area of research. This is particularly important as the therapeutic options for people with chronic pain are increasingly limited.

Read More

Spotlight

Adamed Laboratorios S.L.U.

ADAMED is an international laboratory specializing in Central Nervous System (CNS) and in the area of ​​Gynecology with Adamed Woman. With a young and dynamic style, we offer new answers adapted to the daily needs of the specialist in these areas. Our presence in Spain is backed by a solid position in R & D, giving us completely to innovation, quality and service. Dedicating ourselves to our work in body and mind. MISSION: Develop and offer products and services of the best quality.

Related News

GPs need training to tackle chronic opioid use

medicalxpress | May 13, 2019

GPs must be better-equipped to support patients to manage the psychological challenge of reducing their opioid use—according to new research from the University of East Anglia. The recommendation is part of a toolkit being launched today to help GPs reduce the amount of opioids they prescribe. The toolkit outlines seven areas of best practice to tackle chronic opioid use—based on international research evidence, the experiences of health organisations and individual practitioners. It comes after figures for England and Wales revealed an increase in opioid prescriptions of more than 60 per cent over the last decade—from 14 million in 2008 to 23 million last year.

Read More

FDA approves new medication for dry eye disease

FDA | July 12, 2016

The U.S. Food and Drug Administration today approved safety labeling changes for a class of antibiotics, called fluoroquinolones, to enhance warnings about their association with disabling and potentially permanent side effects and to limit their use in patients with less serious bacterial infections. "Fluoroquinolones have risks and benefits that should be considered very carefully," said Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research. "It's important that both health care providers and patients are aware of both the risks and benefits of fluoroquinolones and make an informed decision about their use

Read More

GPs need training to tackle chronic opioid use

medicalxpress | May 13, 2019

GPs must be better-equipped to support patients to manage the psychological challenge of reducing their opioid use—according to new research from the University of East Anglia. The recommendation is part of a toolkit being launched today to help GPs reduce the amount of opioids they prescribe. The toolkit outlines seven areas of best practice to tackle chronic opioid use—based on international research evidence, the experiences of health organisations and individual practitioners. It comes after figures for England and Wales revealed an increase in opioid prescriptions of more than 60 per cent over the last decade—from 14 million in 2008 to 23 million last year.

Read More

FDA approves new medication for dry eye disease

FDA | July 12, 2016

The U.S. Food and Drug Administration today approved safety labeling changes for a class of antibiotics, called fluoroquinolones, to enhance warnings about their association with disabling and potentially permanent side effects and to limit their use in patients with less serious bacterial infections. "Fluoroquinolones have risks and benefits that should be considered very carefully," said Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research. "It's important that both health care providers and patients are aware of both the risks and benefits of fluoroquinolones and make an informed decision about their use

Read More

Events